Table 1.
Clinical characteristics of the participants and correlation for TDM and BDNF level.
| Groups | Maingroups | Subgroups | Total | Control Group | |||||
|---|---|---|---|---|---|---|---|---|---|
| Value 1 |
LTG-mono
(N=17) |
LTG-poly (N=17) | OXC-mono (N=17) | OXC-poly (N=17) | Non LTG+OXC (N=10) |
ZNS
(N=12) |
LCM
(N=8) |
Total patients (N=80) | Control (N=13) |
| AGE (year) | 31.1±10.7 | 34.6±9.6 | 32.7±13.2 | 36.3±11.1 | 35.5±11.7 | 33.9±10.3 | 35.2±9.0 | 34.4±10.6 | 36.7±7.3 |
| HEIGHT (cm) | 166.5±10.0 | 160.7±13.0 | 166.3±9.1 | 169.2±5.7 | 165.4±9.6 | 167.1±8.4 | 163.7±14.7 | 166.4±10.1 | 170.1±11.1 |
| WEIGHT (kg) | 71.7±16.2 | 69.0±18.6 | 69.4±15.3 | 69.1±12.9 | 67.4±17.6 | 70.5±14.9 | 68.9±21.8 | 70.9±15.8 | 78.3±16.3 |
| WBC (10ʌ3/µL) | 7.0±1.2 | 6.3±1.3 | 7.3±1.2 | 7.6±3.8 | 6.2±2.0 | 6.5±1.5 | 7.6±1.3 | 6.9±2.0 | 6.4±1.8 |
| PLT 10ʌ3/µL) | 254.5±37.8 | 241.9±67.0 | 256.4±57.2 | 255.3±58.8 | 226.4±39.0 | 253.6±65.3 | 259.5±61.4 | 250.3±54.7 | 219.5±6.4 |
| AST (U/L) | 17.6±3.0 | 19.1±10.9 | 18.7±5.9 | 17.7±4.6 | 16.1±3.5 | 15.2±3.4 | 16.4±4.2 | 17.8±6.0 | 17.5±6.4 |
| ALT (U/L) | 15.1±7.0 | 22.7±18.0 | 18.1±8.7 | 18.8±7.3 | 15.3±7.1 | 17.9±9.4 | 16.2±7.3 | 18.3±10.6 | 24.0±12.7 |
| CREATININE (mg/dL) | 0.8±0.2 | 0.7±0.1 | 0.7±0.1 | 0.8±0.2 | 0.8±0.3 | 0.8±0.2 | 0.7±0.1 | 0.8±0.2 | 0.8±0.1 |
| AED (number) | 1.0±0 | 2,59±0.7 | 1.0±0.0 | 2.8±0.9 | 3.2±0,6 | 2.7±0.7 | 3.4±0.5 | 2.0±1.1 | - |
| AO (year) | 17.8±12.2 | 12.2±10.7 | 19.3±13.6 | 13.7±9.5 | 14.5±16.0 | 13.3±14.0 | 4.9±3.6 | 15.7±12.1 | - |
| Groups | Maingroups | Subgroups | Total | Control group | |||||
| Value |
LTG-mono (N=16) |
LTG-poly (N=16) | OXC-mono (N=16) | OXC-poly (N=15) | Non LTG+OXC (N=10) |
ZNS (N=11) |
LCM (N=8) |
Total patients (N=75) | Control (N=13) |
| BDNF1 (ng/mL) | 7.9±4.1 | 7.9±2.8 | 8.6±4.1 | 8.0±2.7 | 9.5±3.6 | 6.7±2.2 | 9.7±3.6 | 8.3±3.5 | 6.7±3.4 |
| Correlations¥ | - | - | - | - | - | - | - | - | - |
| TDM LTG (µg/mL) | n.s | n.s. | - | - | - | n.s. | - | n.s. | - |
| TDM OXC 2 (µg/mL) | - | - | rho=-0.515, p=0.041 | n.s. | - | - | n.s. | n.s. | - |
| TDM ZNS (µg/mL) | - | rho=-0.829, p=0.042 | - | n.s. | n.s. | n.s. | - | n.s. | - |
| TDM LCM (µg/mL) | - | - | - | n.s. | n.s. | - | n.s. | n.s. | - |
| TDM CBZ (µg/mL) | - | n.s. | - | - | n.s. | - | n.s. | n.s. | - |
| TDM CBZ-E (µg/mL) | - | n.s. | - | - | n.s. | - | n.s. | n.s. | - |
| TDM PRM (µg/mL) | - | - | - | - | - | - | - | n.s. | - |
| LTG(mg) | n.s | n.s. | - | - | - | n.s. | - | n.s. | - |
| OXC (mg) | - | - | n.s. | n.s. | - | - | n.s. | n.s. | - |
| ZNS (mg) | - | n.s. | - | n.s. | - | rho=-0.647, p=0.031 | - | n.s. | - |
| LCM (mg) | - | - | - | n.s. | rho=-0.850, p=0.015 | - | rho=-0.741, p=0.036 | rho=-0.714, p=0.006 | - |
| CBZ (mg) | - | n.s. | - | - | n.s. | n.s. | n.s. | n.s. | - |
| VPA (mg) | - | - | - | - | - | - | - | n.s. | - |
| LEV (mg) | - | n.s. | - | n.s. | n.s. | n.s. | n.s. | n.s. | - |
| TPM (mg) | - | - | - | - | - | - | - | n.s. | - |
1Data are expressed as means ± SD. WBC; White Blood Cells, PLT; Platelet, AST; Aspartate Aminotransferase, ALT; Alanine Aminotransferase, AED; The number of antiepileptic drug, AO; The age of onset of the patients, BDNF: Brain-derived neuroprophic factor, ¥BDNF levels and TDM values correlations for each groups. n.s.: not significant. 2This data is expressed as MHD (Mono Hydroxy Derivative of OXC) concentration. LTG; Lamotrigine OXC; Oxcarbazepine, ZNS; Zonisamide, LCM; Lacosamide, CBZ; Carbamazepine, CBZ-E; Carbamazepine epoxide, PRM; Primidone, LEV; Levetiracetam, VPA; Valproic acid, TPM; Topiramate.